Study protocol of the PIMPI-project, a cohort study on acceptance, tolerability and immunogenicity of second trimester maternal pertussis immunization in relation to term and preterm infants.

Immink, Maarten MBekker, Mireille Nde Melker, Hester ERots, Nynke YSanders, Elisabeth A Mvan der Maas, Nicoline A T2021-09-212021-09-212021-09-033447949110.1186/s12879-021-06559-whttp://hdl.handle.net/10029/625273Maternal immunization confers passive immunity to the fetus by transplacental antibody transfer. Infants may be better protected against pertussis if the mother received a diphtheriae, tetanus and acellular pertussis (Tdap) vaccination in the second trimester of pregnancy compared to the third trimester. This study evaluates IgG antibody concentrations in term and preterm infants at birth and 2 months after birth after maternal Tdap-vaccination between 200 and 240 w of gestation vs third trimester Tdap-vaccination. Further aims are assessing the determinants that underlie acceptance of second trimester maternal Tdap-vaccination as well as the tolerability of vaccination.en© 2021. The Author(s).AcceptanceImmunogenicityMaternal immunizationPertussisPrematurityTolerabilityVaccinationStudy protocol of the PIMPI-project, a cohort study on acceptance, tolerability and immunogenicity of second trimester maternal pertussis immunization in relation to term and preterm infants.Article1471-2334BMC Infect Dis 2021; 21(1):897